Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenkangling
- Development stage
- Phase 4
- Lead developer
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Administration
- Oral
01
Overview
Shenkangling is a Traditional Chinese Medicine (TCM) decoction primarily developed and studied by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. It is specifically indicated for the treatment of renal ischemia-reperfusion injury, particularly in patients exhibiting the Kidney Deficiency and Blood Stasis syndrome. The therapy is often administered to patients undergoing procedures like partial nephrectomy or renal exploration, where blood flow to the kidney is temporarily interrupted. As a TCM formulation, its mechanism involves a multi-component approach to tonify kidney function and improve blood circulation to mitigate oxidative stress and inflammatory damage associated with reperfusion.
- Other names
- Shenkangling decoction
02
Targets
ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10)ADAM17 (A disintegrin and metalloprotease 17)CXCL16 (C-X-C motif chemokine ligand 16)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)RELA (Nuclear Factor Kappa B Subunit p65)SPP1 (Osteopontin)TGFB1 (Transforming growth factor Beta-1 proprotein)TNFA (Tumor necrosis factor alpha (soluble))SARS-CoV-2 spikeMAPK3 (Mitogen-activated protein kinase 1)JNK (Mitogen-activated protein kinase kinase kinase family)MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on Shenkangling.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenkangling.